The Cardiovascular Impacts of Electronic Cigarettes in Comparison to the Use of Nicotine Replacement Patches

Smoking, Tobacco Clinical Trial

— VAPOUR  

Official title:

The Cardiovascular Impacts of Electronic Cigarettes to the Use of Nicotine Replacement Patches

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03358953
• Other study ID #: GN16CH051
• Status: Completed
• Phase: N/A
• Start date: December 17, 2016
• Est. completion date: July 13, 2018

Study information

• Verified date: September 2018
• Source: NHS Greater Glasgow and Clyde
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In Scotland tobacco-related illnesses account for in excess of 56,000 hospital admissions and a quarter of deaths each year. The resultant financial impact on NHS Scotland is over £300 million per annum. To minimise the clinical and financial burden of tobacco on national healthcare systems, Scotland's tobacco control strategy aims to create a "tobacco-free" generation by 2034, with the prevalence of smoking in the adult population reduced to ≤5 %. The multifaceted approach focuses upon tobacco prevention, protection and cessation.

In relation to smoking cessation, the use of EC has exponentially increased since 2011, and EC are presently the most popular nicotine replacement product used in England. The Public Health England (PHE) Report published in August 2015 advocates the use of EC when other smoking cessation aids have failed.

Description:

Tobacco smoking (TS) remains a major health challenge for people in Scotland. EC are presently the most popular nicotine replacement product used in England. Recently NHS Greater Glasgow and Clyde (NHSGGC) have, like other Health Boards and Trusts in the UK, lifted the ban on ECs on hospital grounds. This decision has been based on recent evidence that ECs appear to be less harmful when compared to TS but it is acknowledged that the short- and long-term sequelae of ECs remain unknown. Systematic research focusing on the effectiveness of ECs on cardiovascular and pulmonary phenotypes is urgently needed.

The VAPOUR pilot study is a randomised control trial (RCT) investigating the short-term cardiorespiratory effects of EC in comparison to nicotine replacement patches (NRP) in smokers following 12 weeks of smoking cessation support with NHSGG&C Smokefree Community Services. We hypothesise that both EC and NRP users will experience improvements in cardiovascular and pulmonary function; but the effects may be less pronounced in EC users.

The data generated from the pilot study will be invaluable for sample size and power estimation towards the development of a larger scale study. If the data generated from such a trial demonstrate that EC have short-term cardiovascular and pulmonary health effects, this may reduce tobacco associated morbidity and mortality, improve patient care and minimise NHS healthcare costs, and lead to the development of long term studies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: July 13, 2018
• Est. primary completion date: July 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Aged between 18-65 years and wish to stop smoking. Smoker of at least 1-15 tobacco cigarette (TC) per day for = six months Committed to attending weekly support sessions with NHSGGC Smokefree Services Must be willing to stop smoking tobacco cigarettes with the use of either nicotine replacement patches or an electronic cigarette with nicotine containing e-liquid.

Exclusion Criteria:

• Breastfeeding or pregnancy Use of EC or NRP within the past three months Uncontrolled hypertension - Blood pressure =165/95 mmHg

Established history of cardiovascular defined as:

Unstable angina, heart failure New York Heart Association (NYHA) Functional Classification classes III - IV Recent stroke, myocardial infarction, coronary artery bypass graft or percutaneous coronary angiogram within the last 3 months.

Established renal disease defined as eGFR <45 Established history of peripheral vascular disease Established history of Chronic Obstructive Pulmonary Disease. Illicit drug use Severe concurrent medical condition that would prevent participation in study procedures or malignant neoplasm or with life expectancy = 3 months.

Major depressive illness or other psychiatric conditions. Participants who decline participation in the study or who are unable to provide informed consent

• History of allergies to active substances, excipients or delivery device (patch) in NRP or EC

• NRP: See current Summary of Product Characteristics

• EC: Nicotine, Propylene Glycol (PG), Glycerol and water.

Related Conditions & MeSH terms

• Smoking, Tobacco

Intervention

Device:
• Electron Cigarette
Blended Tobacco flavour, 18mg/ml
• Nicotine Replacement Patch
NiQuitin 21mg

Locations

Country	Name	City	State
United Kingdom	Glasgow Clinical Research Facility	Glasgow	Scotland

Sponsors (1)

Lead Sponsor	Collaborator
NHS Greater Glasgow and Clyde

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in endothelial function as assessed by flow mediated dilation	Change in endothelial function as assessed by flow mediated dilation	12 weeks
Secondary	Changes in respiratory function assessed through pulmonary function tests	Changes in respiratory function assessed through pulmonary function tests	12 weeks
Secondary	Changes in endothelial function assessed by Endo-PAT2000, a non-invasive technique	Changes in endothelial function assessed by Endo-PAT2000, a non-invasive technique	12 weeks
Secondary	• Changes in cardiovascular parameters through non-invasive haemodynamic measurements	• Changes in cardiovascular parameters through non-invasive haemodynamic measurements	12 weeks
Secondary	• Changes in cardiovascular risk factor profile as assess through biomarkers markers of inflammation	• Changes in cardiovascular risk factor profile as assess through biomarkers markers of inflammation	12 weeks
Secondary	• Changes in endothelial micoparticles	• Changes in endothelial micoparticles	12 weeks